UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

Breast cancer research and treatment, 2019-06, Vol.175 (3), p.595-603

2019

Volltextzugriff (PDF)

Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial

Annals of oncology, 2024-03, Vol.35 (3), p.293-301

2024

Volltextzugriff (PDF)

16INCombining PARP inhibitors with CPI

Annals of oncology, 2018-03, Vol.29 (suppl_3)

Lynce, F

2018

Volltextzugriff (PDF)

Combining PARP inhibitors with CPI

Annals of oncology, 2018-03, Vol.29, p.iii2-iii2

Lynce, F.

2018

Volltextzugriff (PDF)

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

The New England journal of medicine, 2021-04, Vol.384 (16), p.1529-1541

2021

Volltextzugriff (PDF)

Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer

OncoTargets and therapy, 2022-04, Vol.15, p.471-478

2022

Volltextzugriff (PDF)

342MO Metastatic hormone receptor-positive breast cancer outcomes in 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants: Real-world data analysis of genomics and targeted therapy sequencing

Annals of oncology, 2024-09, Vol.35, p.S358-S358

2024

Volltextzugriff (PDF)

285P Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study

Annals of oncology, 2023-10, Vol.34, p.S298-S298

2023

Volltextzugriff (PDF)

206P HER2-low inflammatory breast cancer (IBC): Clinicopathologic features and prognostic implications

Annals of oncology, 2022-09, Vol.33, p.S629-S630

2022

Volltextzugriff (PDF)

Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer

Current breast cancer reports, 2018, Vol.10 (4), p.241-250

2018

Volltextzugriff (PDF)

P1578Global longitudinal strain in the SAFE-HEaRT study (Cardiac SAFEty of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function)

European heart journal, 2018-08, Vol.39 (suppl_1)

2018

Volltextzugriff (PDF)

177P Oncotype DX breast recurrence score (ODX RS) and gBRCAm in pts with HR+/HER2-negative early breast cancer (eBC) in a retrospective cohort

ESMO open, 2023-05, Vol.8 (1), p.101454, Article 101454

2023

Volltextzugriff (PDF)

Abstract PD8-04: Racial differences in the molecular landscape of breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.PD8-04-PD8-04

2017

Volltextzugriff (PDF)

Abstract P6-10-05: UPTAKE study - Uptake of preventive surgeries among Latinas with BRCA1/2 mutations

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P6-P6-10-05

2018

Volltextzugriff (PDF)

Abstract P6-20-07: Efficacy and safety of CB-839, a small molecule inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer (TNBC): Initial findings from a multicenter, open-label phase 2 study

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-20-07

2019

Volltextzugriff (PDF)

Abstract OT3-04-01: Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: The OXEL study

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-04-01-OT3-04-01

2019

Volltextzugriff (PDF)

152P Inflammatory breast cancer (IBC) in low and middle-income countries (LMICs): Knowledge, and practice patterns - The BRIDGES study

ESMO open, 2024-05, Vol.9, p.103139, Article 103139

2024

Volltextzugriff (PDF)

Abstract OT2-01-09: PALINA: A phase II safety study of pal bociclib in combination with letrozole in A frican American women with hormone receptor positive HER2 negative advanced breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT2-01-09-OT2-01-09

2017

Volltextzugriff (PDF)

Abstract PD5-02: Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple-negative breast cancer beyond BRCA : (TOPACIO/Keynote-162)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.PD5-02-PD5-02

2019

Volltextzugriff (PDF)

Abstract P3-10-02: Increasing participation in research - breast cancer (Inspire-BrC)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P3-P3-10-02

2017

Volltextzugriff (PDF)

Abstract P2-12-03: BRCA1/2 testing in an urban population of black women (BW)

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P2-P2-12-03

2013

Volltextzugriff (PDF)

Abstract P3-04-01: ESR1 mutations, ESR1 fusions and co-occurring alterations assessed in breast cancer tumors

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P3-P3-04-01

2017

Volltextzugriff (PDF)

12P HER2DX in HER2-positive (HER2+) inflammatory breast cancer (IBC): A correlative analysis from a phase II clinical trial

ESMO open, 2023-05, Vol.8 (1), p.101236, Article 101236

2023

Volltextzugriff (PDF)

Abstract OT1-1-12: SAFE-HEaRt: A pilot study assessing the cardiac SAFEty of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.OT1-1-12-OT1-1-12

2013

Volltextzugriff (PDF)

Obesity in adult lymphoma survivors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e19509-e19509

2010

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(41)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial

16INCombining PARP inhibitors with CPI

Combining PARP inhibitors with CPI

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer

342MO Metastatic hormone receptor-positive breast cancer outcomes in 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants: Real-world data analysis of genomics and targeted therapy sequencing

285P Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study

206P HER2-low inflammatory breast cancer (IBC): Clinicopathologic features and prognostic implications

Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer

P1578Global longitudinal strain in the SAFE-HEaRT study (Cardiac SAFEty of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function)

177P Oncotype DX breast recurrence score (ODX RS) and gBRCAm in pts with HR+/HER2-negative early breast cancer (eBC) in a retrospective cohort

Abstract PD8-04: Racial differences in the molecular landscape of breast cancer

Abstract P6-10-05: UPTAKE study - Uptake of preventive surgeries among Latinas with BRCA1/2 mutations

Abstract P6-20-07: Efficacy and safety of CB-839, a small molecule inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer (TNBC): Initial findings from a multicenter, open-label phase 2 study

Abstract OT3-04-01: Nivolumab or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer (TNBC) with residual disease following neoadjuvant chemotherapy: The OXEL study

152P Inflammatory breast cancer (IBC) in low and middle-income countries (LMICs): Knowledge, and practice patterns - The BRIDGES study

Abstract OT2-01-09: PALINA: A phase II safety study of pal bociclib in combination with letrozole in A frican American women with hormone receptor positive HER2 negative advanced breast cancer

Abstract PD5-02: Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple-negative breast cancer beyond BRCA : (TOPACIO/Keynote-162)

Abstract P3-10-02: Increasing participation in research - breast cancer (Inspire-BrC)

Abstract P2-12-03: BRCA1/2 testing in an urban population of black women (BW)

Abstract P3-04-01: ESR1 mutations, ESR1 fusions and co-occurring alterations assessed in breast cancer tumors

12P HER2DX in HER2-positive (HER2+) inflammatory breast cancer (IBC): A correlative analysis from a phase II clinical trial

Abstract OT1-1-12: SAFE-HEaRt: A pilot study assessing the cardiac SAFEty of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function

Obesity in adult lymphoma survivors

Suchergebnisse filtern